
MRD Testing Could Cut Costs, Refine Blood Cancer Care: Ravi Vij, MD, MBA
Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity.
Measurable residual disease (MRD) testing is becoming an increasingly important tool in managing
In an interview with The American Journal of Managed Care® (AJMC®), Ravi Vij, MD, MBA, professor of medicine in the Division of Medical Oncology at Washington University School of Medicine, explained how MRD testing is already predictive in
Vij emphasized that future algorithms will need to determine whether intensifying therapy for patients with MRD-positive disease or abbreviating treatment for those with sustained MRD negativity leads to better outcomes. Once sufficient data are available, Vij said MRD-guided care could help reduce costs, minimize treatment-related toxicity, and extend the durability of disease control for many patients.
This transcript has been lightly edited; captions were auto-generated.
Transcript
As MRD testing becomes more common in blood cancers, what clinical or financial changes are necessary to make MRD-guided care a standard part of treatment for all patients?
I think MRD is certainly a growing part of our patient management in a variety of hematological malignancies. In some, it is already not only prognostic, but predictive in that you can decide your course of treatment based on the results of the MRD, like in acute lymphoblastic leukemia [and] some cases of chronic lymphocytic leukemia.
In
I think that we just need more data, but yes, once that becomes available it could actually reduce cost by—in several cases—
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.